Literature DB >> 31250167

Clinical value of a [18F]-FDG PET-CT muscle-to-muscle SUV ratio for the diagnosis of active dermatomyositis.

Nihal Martis1, Philippe Viau2, Thierry Zenone3, Fanny Andry4, Aurélie Grados5, Mikael Ebbo5, Emeline Castela6, Benoit Brihaye7, Eric Denis8, Stéphane Liguori9, Alexandra Audemard10, Yoland Schoindre11, Anne-Sophie Morin12, Benjamin Terrier13, Laurent Marcq8, Nicolas Mounier14, Olivier Lidove15, Jean-Philippe Chaborel16, Denis Quinsat8.   

Abstract

OBJECTIVE: To study a muscle-to-muscle standardised uptake value (SUV) ratio with FDG-PET/CT (FDG-PET) as a marker for the detection of disease activity in dermatomyositis (DM).
METHODS: Patients with DM (n = 24) who met the European Neuro-Muscular Centre diagnostic criteria were retrospectively identified over a 3-year period through a national survey. Muscle biopsy was performed in all patients. Maximum SUV was measured in proximal muscles (SUVPROX) that had the highest radiotracer uptake on visual grading as well as in the musculus longissimus thoracis (SUVMLT), whereas mean SUV was measured for the liver (SUVLIV). Muscle-to-liver SUV ratios for either muscle group were compared and a SUVPROX/SUVMLT ratio was calculated. SUVPROX/SUVMLT of DM patients were compared with age- and sex-matched control subjects (n = 24) with melanoma who had received FDG-PET scans.
RESULTS: DM patients presented with proximal and symmetrical muscle uptake. Differences in SUVPROX/SUVLIV and SUVMLT/SUVLIV ratios in DM subjects were significant (p < 0.001). SUVPROX/SUVMLT ratios in DM and their controls also differed significantly (p = 0.0012). The SUVPROX/SUVMLT ratio threshold between DM subjects and controls was 1.73 with a sensitivity of 50% (CI95%, 29.1 to 70.9%) and specificity at 83.3% (CI95%, 62.6 to 95.3%). When amyopathic DM patients were removed from the analysis, specificity was increased to 95% (CI95%, 75.1 to 99.9%) with a likelihood ratio of 10 and an AUC of 83.4% (CI95%, 71.4 to 95.4%).
CONCLUSION: A muscle-to-muscle SUVPROX/SUVMLT ratio with a cut-off value of 1.73 in FDG-PET imaging might serve as a non-invasive marker to determine disease activity in dermatomyositis. KEY POINTS: • [18F]-FDG PET-scanner standardised uptake value (SUV) could reflect disease activity in dermatomyositis (DM). • A ratio of SUV in proximal muscles (SUVPROX) to SUV in musculus longissimus thoracis (SUVMLT) could be used to determine active DM. • Active disease is suspected for SUV PROX /SUV MLT ratios greater than 1.73.

Entities:  

Keywords:  Amyopathic dermatomyositis; Dermatomyositis; Fluorodeoxyglucose F18; Myositis; Positron-emission tomography

Mesh:

Substances:

Year:  2019        PMID: 31250167     DOI: 10.1007/s00330-019-06302-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  21 in total

1.  Combining MRI and muscle biopsy improves diagnostic accuracy in subacute-onset idiopathic inflammatory myopathy.

Authors:  Janneke Van De Vlekkert; Mario Maas; Jessica E Hoogendijk; Marianne De Visser; Ivo N Van Schaik
Journal:  Muscle Nerve       Date:  2015-02       Impact factor: 3.217

2.  Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent.

Authors:  J Emami; H C Gerstein; F M Pasutto; F Jamali
Journal:  Can J Physiol Pharmacol       Date:  1999-02       Impact factor: 2.273

3.  18F-Fluorodeoxyglucose positron emission tomography for the assessment of myositis: a case series.

Authors:  Nicolo Pipitone; Annibale Versari; Giulio Zuccoli; Gabriele Levrini; Pierluigi Macchioni; Gianluigi Bajocchi; Carlo Salvarani
Journal:  Clin Exp Rheumatol       Date:  2012-08-29       Impact factor: 4.473

Review 4.  Malignancy and myositis: novel autoantibodies and new insights.

Authors:  Albert Selva-O'Callaghan; Ernesto Trallero-Araguás; Josep M Grau-Junyent; Moisés Labrador-Horrillo
Journal:  Curr Opin Rheumatol       Date:  2010-11       Impact factor: 5.006

5.  Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients.

Authors:  Stine Bjørn Kristensen; Søren Hess; Henrik Petersen; Poul Flemming Høilund-Carlsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-21       Impact factor: 9.236

6.  Impact of blood glucose, diabetes, insulin, and obesity on standardized uptake values in tumors and healthy organs on 18F-FDG PET/CT.

Authors:  Karen A Büsing; Stefan O Schönberg; Joachim Brade; Klaus Wasser
Journal:  Nucl Med Biol       Date:  2012-12-08       Impact factor: 2.408

7.  Paraneoplastic syndromes: detection of malignant tumors using [(18)F]FDG-PET.

Authors:  U Berner; C Menzel; D Rinne; S Kriener; N Hamscho; N Döbert; M Diehl; R Kaufmann; F Grünwald
Journal:  Q J Nucl Med       Date:  2003-06

8.  Standardized uptake values of FDG: body surface area correction is preferable to body weight correction.

Authors:  C K Kim; N C Gupta; B Chandramouli; A Alavi
Journal:  J Nucl Med       Date:  1994-01       Impact factor: 10.057

9.  [18F]FDG uptake in proximal muscles assessed by PET/CT reflects both global and local muscular inflammation and provides useful information in the management of patients with polymyositis/dermatomyositis.

Authors:  Shigeru Tanaka; Kei Ikeda; Katsuhiro Uchiyama; Taro Iwamoto; Yoshie Sanayama; Ayako Okubo; Daiki Nakagomi; Kentaro Takahashi; Masaya Yokota; Akira Suto; Kotaro Suzuki; Hiroshi Nakajima
Journal:  Rheumatology (Oxford)       Date:  2013-03-11       Impact factor: 7.580

10.  Clinical values of FDG PET in polymyositis and dermatomyositis syndromes: imaging of skeletal muscle inflammation.

Authors:  Maki Tateyama; Kazuo Fujihara; Tatsuro Misu; Akira Arai; Tomohiro Kaneta; Masashi Aoki
Journal:  BMJ Open       Date:  2015-01-12       Impact factor: 2.692

View more
  2 in total

Review 1.  The Role of Quantitative and Semi-quantitative [18F]FDG-PET/CT Indices for Evaluating Disease Activity and Management of Patients With Dermatomyositis and Polymyositis.

Authors:  Halil Yildiz; Philippe D'abadie; Olivier Gheysens
Journal:  Front Med (Lausanne)       Date:  2022-04-15

Review 2.  MRI and muscle imaging for idiopathic inflammatory myopathies.

Authors:  Samuel Malartre; Damien Bachasson; Guillaume Mercy; Elissone Sarkis; Céline Anquetil; Olivier Benveniste; Yves Allenbach
Journal:  Brain Pathol       Date:  2021-05       Impact factor: 6.508

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.